Cognitive effects and antipsychotic treatment

Psychoneuroendocrinology

Volumn 28, Issue SUPPL. 1, 2003, Pages 27-38

  Kasper, S ^a   Resinger, E ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antipsychotics; Clozapine; Neuropsychological testing; Quetiapine; Risperidone; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYPROHEPTADINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HUMAN; NONHUMAN; OCCUPATION; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSOCIAL CARE; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SOCIAL STATUS; SYMPTOM;

EID: 0037216555     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(02)00115-4     Document Type: Review

References (47)

1. Blyler C.R., Gold J.M. Cognitive effects of conventional antipsychotics: another look. Cognitive Functioning in Schizophrenia: Characteristics, Correlates and Treatment. 1999;Oxford University Press, Oxford.
2. Bryson G., Bell M.D., Kaplan E., Greig T. The functional consequences of memory impairments on initial work performance in people with schizophrenia. J. Nerv. Ment. Dis. 186:1998;610-615.
3. Buchanan R.W., Holstein C., Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry. 36:1994;717-725.
4. Cannon T.D., Zorilla L.E., Shtasel D., Gur R.E., Gur R.C., Marco E.J., Moberg P., Price R.A. Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch. Gen. Psychiatry. 51:1994;651-661.
5. Cassens G., Inglis A.K., Appelbaum P.S., Gutheil T.G. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr. Bull. 16:1990;477-499.
6. Caycedo N., Connell J., Hellewell J.S.E., Deakin J.F.W. Effects of fenfluramine on executive and other cognitive functions. Behav. Pharmacol. 6:(Suppl. 1):1995;33.
7. Censits D.M., Ragland J.D., Gur R.C., Gur R.E. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr. Res. 24:1997;289-298.
8. Chaudhury I.B., Soni S.D., Hellewell J.S.E., Deakin J.F.W. Antisaccade, clinical and motor executive functions in schizophrenia: effects of 5HT2 antagonist, cyproheptadine. Schizophr. Res. 24:1997;212.
9. Faraone S.V., Seidman L.J., Kremen W.S., Pepple J.R., Lyons M.J., Tsuang M.T. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a diagnostic efficiency analysis. J. Abnorm. Psychol. 104:1995;286-304.
10. Finamore T.L., Seybold K.S., Noble M., Port R.L. Contributions of hippocampal cellular damage and NMDA receptor dysfunction to behavioral markers of schizophrenia. Int. J. Neurosci. 109:2001;61-70.
11. Fleming K., Kalali A., Yeh C., Vargo D.L., Thyrum P.T., Potkin S.G. The neurocognitive effects of quetiapine (Seroquel, ICI 204636). Schizophr. Res. 24:1997;197.
12. Gold J., Goldberg T., Kleinman J., Weinberger D. The effects of symptomatic state and pharmacological treatment on the neuropsychological test performance of patients with schizophrenia and affective disorders. Mohr E., Brouwers P. Handbook of Clinical Trials: The Neurobehavioural Approach. 1991;185-216 Swets and Zeitlinger, Lisse.
13. Gold J.M., Harvey P.D. Cognitive deficits in schizophrenia. Psychiatr. Clin. North Am. 16:1993;295-312.
14. Gold J.M., Queern C., Iannone V.N., Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am. J. Psychiatry. 156:1999;1944-1950.
15. Goldberg T.E., Greenberg R.D., Griffin S.J., Gold J.M., Kleinman J.E., Picker D., Schulz S.C., Weinberger D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry. 162:1993;43-48.
16. Goldman-Rakic P.S., Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 23:1997;437-458.
17. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry. 153:1996;321-330.
18. Green M.F., Marshall B.D. Jr., Wirshing W.C., Ames D., Marder S.R., McGurk S., Kern R.S., Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. J. Psychiatry. 154:1997;799-804.
19. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry. 34:1993;702-712.
20. Harvey P.D., Howanitz E., Parrella M., White L., Davidson M., Mohs R.C., Hoblyn J., Davis K.L. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am. J. Psychiatry. 155:1998;1080-1086.
21. Hoff A.L., Faustman W.O., Wieneke M., Espinoza S., Costa M., Wolkowitz O., Csemansky J.G. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 15:1996;361-369.
22. Jaeger J., Douglas E. Neuropsychiatric rehabilitation for persistent mental illness. Psychiatr. Q. 63:1992;71-94.
23. Kasper S., Tauscher J., Willeit M., Stamenkovic M., Neumeister A., Küfferle B., Barnas C., Stastny J., Praschak-Reider N., Pezawas L., de Zwaan M., Quiner S., Pirker W., Asenbaum S., Podreka I., Brücke T. Receptor and transporter imaging-studies in schizophrenia, depression, bulimia and Tourette's disorder. Implications for psychopharmacology. World J. Biol. Psychiatry. 3:2002;133-146.
24. Kee K.S., Kern R.S., Marshall B.D. Jr., Green M.F. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophr. Res. 31:1998;159-165.
25. Kern R.S., Green M.F., Marshall B.D. Jr., Wirshing W.C., Wirshing D., McGurk S.R., Marder S.R., Mintz J. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr. Bull. 25:1999;223-232.
26. Kern R.S., Green M.F., Marshall B.D. Jr., Wirshing W.C., Wirshing D., McGurk S., Marder S.R., Mintz J. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biol. Psychiatry. 44:1998;726-732.
27. Lee M.A., Thompson P.A., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry. 55:(Suppl. 8):1994;82-87.
28. Meltzer H.Y., Thompson P.A., Lee M.A., Ranjan R. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology. 14:1996;27S-33S.
29. Morice R., Delahunty A. Frontal/executive impairments in schizophrenia. Schizophr. Bull. 22:1996;125-137.
30. Mortimer A.M. Cognitive function in schizophrenia: do neuroleptics make a difference? Pharmacol. Biochem. Behav. 56:1996;789-795.
31. Mortimer A.M., Dye S. Remediation of neuropsychological impairments with clozapine. Schizophr. Res. 24:1997;187.
32. Nuechterlein K.H., Dawson M.E. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr. Bull. 10:1984;160-203.
33. Purdon S.E. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr. Res. 35:(Suppl.):1999;S51-S60.
34. Purdon S.E. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. J. Psychiatry Neurosci. 25:2000;108-116.
35. Purdon S.E., Jones B.D., Stip E., Labelle A., Addington D., David S.R., Breier A., Tollefson G.D. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian collaborative group for research in schizophrenia. Arch. Gen. Psychiatry. 57:2000;249-258.
36. Purdon S., Malla A., Labelle A., Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 26:2001;137-149.
37. Rossi A., Mancini F., Stratta P., Mattei P., Gismondi R., Pozzi F., Casacchia M. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr. Scand. 95:1997;40-43.
38. Sax K.W., Strakowski S.M., Keck P.E. Jr. Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr. Res. 33:1998;151-155.
39. Saykin A.J., Gur R.C., Gur R.E., Mozley P.D., Mozley L.H., Resnick S.M., Kester D.B., Stafiniak P. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch. Gen. Psychiatry. 48:1991;618-624.
40. Skarsfeldt T. Differential effect of novel and reference antipsychotics on place navigation of rats in Morris water maze. Eur. Neuropsychopharmacol. 6:(Suppl. 3):1996;189. (abstract P-19-18).
41. Sharma T., Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J. Clin. Psychopharmacol. 2:(Suppl. 1):1998;12S-19S.
42. Spohn H.E., Strauss M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychol. 98:1989;367-380.
43. Stip E., Lussier I., Babai M., Fabian J.L., Link C. Seroquel and cognitive improvement in patients with schizophrenia. Biol. Psychiatry. 40:1996;434-435.
44. van den Bosch R.J., Rombouts R.P. Causal mechanisms of subjective cognitive dysfunction in schizophrenic and depressed patients. J. Nerv. Ment. Dis. 186:1998;364-368.
45. Velligan D.I., Mahurin R.K., Diamond P.L., Hazleton B.C., Eckert S.L., Miller A.L. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr. Res. 25:1997;21-31.
46. Velligan D.I., Newcomer J., Pultz J., Csernansky J., Hoff A.L., Mahurin R., Miller A.L. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr. Res. 53:2002;239-248.
47. Velligan D.I., Bow-Thomas C.C. Executive function in schizophrenia. Semin. Clin. Neuropsychiatry. 4:1999;24-33.